d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
- 17 June 2002
- journal article
- clinical trial
- Published by Elsevier in Schizophrenia Research
- Vol. 56 (1-2) , 19-23
- https://doi.org/10.1016/s0920-9964(01)00220-1
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Placebo-Controlled Trial of Glycine Added to Clozapine in SchizophreniaAmerican Journal of Psychiatry, 2000
- Clozapine treatment increases serum glutamate and aspartate compared to conventional neurolepticsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- The Glutamatergic Dysfunction Hypothesis for SchizophreniaHarvard Review of Psychiatry, 1996
- Glutamate Receptor Dysfunction and SchizophreniaArchives of General Psychiatry, 1995
- Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptorsEuropean Journal of Pharmacology, 1995
- d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1994
- Actions of ?-cycloserine at the ? glycine receptor site in vivoNeuropharmacology, 1991
- d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed inXenopus oocytesBrain Research, 1990
- The schedule for the deficit syndrome: An instrument for research in schizophreniaPsychiatry Research, 1989
- Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus OocytesScience, 1988